Technical Analysis for MCRB - Seres Therapeutics, Inc.

Grade Last Price % Change Price Change
F 19.04 1.33% 0.25
MCRB closed up 1.33 percent on Friday, February 26, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical MCRB trend table...

Date Alert Name Type % Chg
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 1.33%
Lower Bollinger Band Walk Weakness 1.33%
Multiple of Ten Bearish Other 1.33%
Wide Bands Range Expansion 1.33%
Below Lower BB Weakness 1.33%
Older End-of-Day Signals for MCRB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace 2 days ago
Down 5% 2 days ago
Down 3% 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Seres Therapeutics, Inc. Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Development Autoimmune Diseases Antibiotic Inflammatory Bowel Disease Ulcer Colitis Ulcerative Colitis Ecology Diarrhea Antimicrobial Resistance Digestive Diseases Cdi Clostridioides Difficile Clostridium Difficile Clostridium Difficile Infection

Is MCRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 38.5
52 Week Low 2.52
Average Volume 1,081,393
200-Day Moving Average 20.24
50-Day Moving Average 24.77
20-Day Moving Average 24.36
10-Day Moving Average 22.36
Average True Range 2.14
ADX 17.51
+DI 14.88
-DI 32.74
Chandelier Exit (Long, 3 ATRs ) 23.48
Chandelier Exit (Short, 3 ATRs ) 24.08
Upper Bollinger Band 30.02
Lower Bollinger Band 18.69
Percent B (%b) 0.03
BandWidth 46.48
MACD Line -1.52
MACD Signal Line -0.76
MACD Histogram -0.7599
Fundamentals Value
Market Cap 1.74 Billion
Num Shares 91.2 Million
EPS -1.87
Price-to-Earnings (P/E) Ratio -10.20
Price-to-Sales 92.84
Price-to-Book 14.08
PEG Ratio -0.11
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.98
Resistance 3 (R3) 21.85 20.73 21.49
Resistance 2 (R2) 20.73 19.98 20.80 21.33
Resistance 1 (R1) 19.89 19.52 20.31 20.02 21.16
Pivot Point 18.77 18.77 18.99 18.84 18.77
Support 1 (S1) 17.93 18.02 18.35 18.06 16.92
Support 2 (S2) 16.81 17.56 16.88 16.75
Support 3 (S3) 15.97 16.81 16.59
Support 4 (S4) 16.10